Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study
- 8 November 2018
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 25 (2), 205-212
- https://doi.org/10.1111/hae.13616
Abstract
Introduction The THUNDER study provides an analysis of treatment patterns and outcomes in UK patients with severe or moderate haemophilia A (SHA/MHA) in 2015. Methods Patients with SHA or MHA registered with the UK National Haemophilia Database (NHD) were segregated by severity, inhibitor status and age. Haemophilia joint health score (HJHS) was derived from NHD records and treatment regimen and annualized bleed/joint‐bleed rate (ABR/AJBR) from Haemtrack (HT) in HT‐compliant patients. Results We report 1810 patients with SHA and 864 with MHA. Prophylaxis was used in 94.9% (n = 130/137) of HT‐compliant children <12 years with SHA, falling to 74.1% (n = 123/166) aged ≥40 years. Median ABR increased with age (1.0, IQR 0.0‐5.0, <12 years; 3.0 IQR, 1.0‐8.0, ≥40 years). Inhibitors were present in 159 (8.8%) SHA and 34 (3.9%) MHA. Median ABR increased from 2.0 (<12 years) to 21.0 (≥40 years) in SHA inhibitor patients using prophylaxis. Prophylaxis was used by 68.8% of HT‐compliant MHA patients (n = 106) (median FVIII baseline 0.01 IU/mL) associated with a median (IQR) ABR of 3.0 (1.0‐7.0). Median HJHS (n = 453) increased with age in SHA and MHA. Median (IQR) HJHS was higher in SHA inhibitor (17.0, 0.0‐64.5) than non‐ or past inhibitor patients (7.0, 0.0‐23.0). Conclusions Increasing ABR with age persists despite current prophylaxis regimens. SHA and MHA had similar ABR/AJBR and HJHS, leading to a suspicion that a subgroup of MHA may be relatively undertreated. More intensive prophylaxis may improve outcomes, but this requires further study.Keywords
Funding Information
- Roche
This publication has 30 references indexed in Scilit:
- Factor VIII inhibitors in hemophilia A: rationale and latest evidenceTherapeutic Advances in Hematology, 2012
- Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns surveyHaemophilia, 2012
- Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levelsHaemophilia, 2010
- A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia ABritish Journal of Haematology, 2010
- Clinical outcome of moderate haemophilia compared with severe and mild haemophiliaHaemophilia, 2009
- The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis surveyHaemophilia, 2008
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- A survey of factor prophylaxis in the Canadian haemophilia A populationHaemophilia, 2004
- A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacsJournal of Internal Medicine, 1994
- Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and BJournal of Internal Medicine, 1992